Wall Street equity research analysts covering Milestone Pharmaceuticals, trading under the ticker symbol MIST, maintain a consensus twelve-month price target that suggests substantial potential upside from its current market trading value. Based on recent tracking data from financial research platforms, covering analysts have established a median price target hovering around $7.00 per share, with individual estimates ranging from a low target of approximately $2.00 up to a high estimate of $8.00 per share. The overwhelming majority of covering financial institutions maintain positive "Buy" or "Overweight" ratings on the biopharmaceutical enterprise, reflecting confidence in its clinical pipeline developments and therapeutic innovations. Investors closely monitor these forecasts alongside clinical trial milestones and corporate regulatory updates to gauge the future growth trajectory of the clinical-stage cardiovascular medicine developer.